Descriptor: "Zejula®" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Zejula®"' showing total 5 results

Start Over Descriptor "Zejula®"

Author: García Luque, A., Puerro Vicente, M., Sánchez López, P., and López Morán, M. J.
Subjects: *CLINICAL drug trials, *MEDICAL personnel, *HEALTH products, *MEDICAL supplies
Abstract: The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in September, October and November of 2017, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product. [ABSTRACT FROM AUTHOR]
Published: 2021
Full Text: View/download PDF

Author: García Luque, A., Puerro Vicente, M., Sánchez López, P., and López Moran, M. J.
Abstract: Copyright of Sanidad Militar is the property of Ministerio de Defensa, Subdireccion General de Publicaciones y Patrimonio Cultural and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Published: 2018
Full Text: View/download PDF

Author: García Luque, A, Puerro Vicente, M, Sánchez López, P, and López Morán, MJ
Subjects: Mvasi®, Human thrombin, Jorveza®, Niraparib, Trelegy Ellipta®, Ocrevus®, Padeliporfine, Padeliporfina, Human fibrinogen, Budesonida, Umeclidinium, Ocrelizumab, Vilanterol, Budesonide, Zubsolv®, Elebrato Ellipta®, VeraSeal®, Prasterone, Naloxona, Guselkumab, Prasterona, Buprenorfina, Adynovi®, Naloxone, Trombina Humana, Fasenra®, Rurioctocog Alfa Pegol, Nyxoid®, Benralizumab, Tremfya®, Intrarosa®, Buprenorphine, Bevacizumab, Zejula®, Fibrinógeno humano, Fluticasone, Fluticasona, Letermovir, Prevymis®, Tookad®
Abstract: RESUMEN Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en septiembre, octubre y noviembre de 2017. Se trata de opiniones técnicas positivas previas a la autorización y puesta en el mercado del medicamento. SUMMARY The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in September, October and November of 2017, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.
Published: 2018

Author: García Luque,A, Puerro Vicente,M, Sánchez López,P, and López Morán,MJ
Subjects: Mvasi®, Jorveza®, Niraparib, Trelegy Ellipta®, Ocrevus®, Padeliporfina, Budesonida, Umeclidinium, Ocrelizumab, Vilanterol, Zubsolv®, Elebrato Ellipta®, VeraSeal®, Naloxona, Guselkumab, Prasterona, Buprenorfina, Adynovi®, Trombina Humana, Fasenra®, Rurioctocog Alfa Pegol, Nyxoid®, Benralizumab, Tremfya®, Intrarosa®, Bevacizumab, Zejula®, Fibrinógeno humano, Fluticasona, Letermovir, Prevymis®, Tookad®
Abstract: RESUMEN Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en septiembre, octubre y noviembre de 2017. Se trata de opiniones técnicas positivas previas a la autorización y puesta en el mercado del medicamento.
Published: 2018

Abstract: Copyright of ASHP Patient Medication Information - Spanish Version is the property of American Society of Health System Pharmacists and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Published: 2022

Books, media, physical & digital resources

Searchworks